PMN are critical to innate immunity and are fundamental to antibacterial defense. To localize to sites of infection, PMN possess receptors that detect chemoattractant stimuli elicited at the site, such as chemokines, complement split products, or bioactive lipids. Signaling through these receptors stimulates chemotaxis toward the site of infection but also activates a number of biochemical processes, with the result that PMN kill invading bacteria. PMN possess two receptors, CXCR1 and CXCR2, for the N-terminal ELR motif-containing CXC chemokines, although only two chemokine members bind both receptors and the remainder binding only CXCR2. This peculiar pattern in receptor specificity has drawn considerable interest and investigation into whether signaling through each receptor might impart unique properties on the PMN. Indeed, at first glance, CXCR1 and CXCR2 appear to be functionally redundant; however, there are differences. Considering these proinflammatory activities of activating PMN through chemokine receptors, there has been great interest in the possibility that blocking CXCR1 and CXCR2 on PMN will provide a therapeutic benefit. The literature examining CXCR1 and CXCR2 in PMN function during human and modeled diseases will be reviewed, asking whether the functional differences can be perceived based on alterations in the role PMN play in these processes. J. Leukoc [4 -6]. The two human receptors are highly homologous (77% aa identity), and the greatest diversity was focused at three regions: the N terminus (the ligand-binding region), the fourth transmembrane domain, and the C terminus [7, 8] . Both receptors have promoters containing TATA boxes and GC-rich 5Ј-flanking regions [9] .
CXCR1 AND CXCR2 GENETICS
CXCR1 and CXCR2 are expressed on cells, mostly of myeloid lineage, such as mature PMN and monocytes [1] ; however, one or both receptor types can also be expressed in other leukocytes including CD8ϩ T cells [2] and mast cells [3] and nonhematopoietic cell types such as endothelial and epithelial cells [4 -6] . The two human receptors are highly homologous (77% aa identity), and the greatest diversity was focused at three regions: the N terminus (the ligand-binding region), the fourth transmembrane domain, and the C terminus [7, 8] . Both receptors have promoters containing TATA boxes and GC-rich 5Ј-flanking regions [9] .
The cDNA for CXCR1 was cloned by Holmes et al. [10] in 1991 from a human PMN cDNA library. The gene for human CXCR1 (IL-8RA) was subsequently located on chromosome 2q35 [11] . The gene consists of two exons separated by an intron of ϳ1.7 kb, with the entire open-reading frame contained in the second exon [12] , which encodes a protein of 350 aa. CXCR1 has also been identified in several other species, notably, monkeys, bovine, chicken, and rabbits; however, mice and rats, for a long time, have been appreciated to only have a functional CXCR2 homologue. The rat ortholog of CXCR1 does not signal with any of the ligands tested nor did PMN possess mRNA for this receptor [13] . Noteworthy, although there was Southern blot evidence of two CXCR in mice [14] , three recent studies have now reportedly found the putative CXCR1 homologue/ortholog in mice. The first of these murine receptors was mapped to chromosome 1 and found to be expressed in the spleen, kidneys, and liver, with transcripts also found in CD4ϩ T cells, although no known human or mouse chemokines induced G-protein activation of the receptor [15] . As this receptor was found on a wide variety of cells and did not bind PMN chemoattractants, it is unlikely that it is analogous in function to human CXCR1. The second report of a mCXCR1-like gene reported the sequence was 77% homologous to the rat gene for CXCR1 and 58% homologous to human IL-8RA [16] . It was expressed and up-regulated on PMN recruited to the lung in an inflammation model [16] , which may function as a CXCR1 homologue; however, its functional and binding properties have not been characterized sufficiently to make this conclusion. More recently, Fan and coworkers [17] published a comprehensive analysis of their cloned mCXCR1 homologue, which signaled through G proteins and showed regulated mRNA expression in collagen-induced arthritis, but expression specifically on PMN was not shown. A strain of mouse with a targeted mutation of cxcr1 has been developed, but its immunological phenotype has not yet been reported. In addition to mice, a CXCR1 ortholog expressed on PMN but not lymphocytes or macrophages was cloned from guinea pigs. HEK293 cells transfected with this clone migrated in response to CXCL8, which was accompanied by an increase in ERK phosphorylation [18] . Greater details about the homologies between receptor genes and proteins of different species can be found published elsewhere [17] . The finding that rodents may express an ortholog to human IL-8RA suggests that in the future, these models may be useful to study the in vivo relationship between CXCR1 and CXCR2. Meanwhile, research has been conducted using cxcr2 gene knockout mice and receptor blockers (see below), and definitive progress suggests that this has potential as an antiinflammatory therapy; therefore, more research is needed to further confirm the presence and functional relationship of rodent CXCR1 with CXCR2.
The human IL-8RB (CXCR2), cDNA was first cloned in 1991 from an HL-60 cell cDNA library by Murphy and Tiffany [19] . Like CXCR1, CXCR2 maps to chromosome 2, and the mouse homologue maps to chromosome 1. The CXCR2 gene consists of three exons, separated by introns of 3 and 5.4 kb, respectively [20] . The mCXCR2 homologue [14, 21] binds to ELR ϩ CXC ligands, for example, mCXCL1 (KC) [22] and mCXCL2 (MIP-2) [23] . mCXCR2 can also be activated by human GRO chemokines CXCL1-CXCL3 and CXCL8 [21] .
SIGNALING VIA CXCR1 AND CXCR2
Human CXCR1 binds two chemokines, CXCL6 (granulocyte chemotactic protein-2) and CXCL8 (IL-8), with high affinity [24] . Human CXCR2 binds, in addition to the two that bind CXCR1, multiple, different CXC ELRϩ chemokines, including CXCL1 (GRO-␣), CXCL2 (GRO-␤), CXCL3 (GRO-␥), CXCL5 (epithelial cell-derived neutrophil-activating peptide-78), and CXCL7. Recently, an ECM breakdown product, a tripeptide N-acetyl PGP with structural homology to ELRϩ chemokines, was described to bind to CXCR1 and CXCR2 on human PMN and to be chemotactic for rodent neutrophils [25] .
Transmembrane signaling through CXCR1 and CXCR2 plays a role in many PMN antimicrobial functions including chemotaxis, degranulation, and the oxidative burst. Many of the studies deducing these signaling pathways have been conducted on cell lines transfected with single receptor types. For example, transfection of Jurkat cells with a cDNA for CXCR1 or CXCR2, followed by exposure to receptor agonists, revealed that both receptors stimulate changes in free Ca 2ϩ and granule enzyme release [26] . CXCR1 and CXCR2 associate with many ␣ subunits of the heterotrimeric G-protein complex. Gproteins are a class of GTP-binding proteins including G␣, G␤, and G␥ (Fig. 1) . The G␣ subunit binds GDP in its inactive state and GTP in the activated state. When the receptor is activated by ligand binding, bound GDP dissociates from the G␣ subunit, allowing GTP to bind. Cleavage of the GTP terminal phosphate by a GTPase restores the G-protein to its inactive form with bound GDP. Meanwhile, the ␤␥ subunit dissociates from the ␣ subunit resulting in the phosphorylation of the C-terminal tail by GRK. CXCR1 C-terminal tail phosphorylation is required for some processes, such as chemotaxis and receptor internalization, but other signaling pathways are independent of phosphorylation, including PLC activation and 
Ca
2ϩ mobilization, as observed using CXCR1 mutants with truncated C-terminal tails [27] .
The G␤␥ subunit recruits and activates PI3K-␥, which in turn produces PIP3 (Fig. 1) , which activates PKB (Akt) as well as GTPases, resulting in directed cell migration. Mice lacking PLC␤ 2ϩ3 , a key enzyme to generate IP3 and DAG, abrogate CXCL8-induced increases in intracellular calcium concentrations, PKC phosphorylation, p47 phox translocation, and superoxide anion generation but enhance chemokine-mediated chemotaxis [28] . PI3K-␥-deficient mice exhibit a reduction in CXCL8-mediated neutrophil migration, PIP3 generation, Akt phosphorylation, and respiratory burst with a robust increase in intracellular calcium concentration in response to CXCL8 [29] . These results suggest that chemokine-induced chemotaxis is mediated through PI3K-␥-independent and -dependent pathways. Further, CXCL8 activates Ras, MAPK, and ERK1/2 in PMN [30] .
Pertussis-resistant G-proteins G ␣4 and G ␣6 (humans) and G ␣5 (mice) associate with CXCR1 (humans) and CXCR2, as detected by CXCL8-dependent activation of PLC [31] . In addition, they can couple to G i , a pertussis-sensitive G-protein, to release ␤␥ subunits, which in turn, activate the PLC␤2 isoform [31] . Treatment with pertussis toxin revealed that coupling with G i is likely more biologically relevant, as it inhibits CXCL8-induced chemotaxis by PMN [32, 33] . This suggests that there are no differences in the G-protein subunits between CXCR1 and CXCR2, despite differences in their cytoplasmic C-terminal domains.
Despite evidence that the two receptors signal through similar G proteins, there are marked differences in the activation of signaling cascades between CXCR1 and CXCR2, which may identify disparate functions. Inhibition of CXCR1, but not CXCR2, reportedly resulted in a decrease in superoxide anion production by PMN, indicating that CXCR1 is important in oxidative burst [26, 34] . CXCL8-induced PLD activation is achieved through CXCR1 but not CXCR2 activation [34] . More specifically, Lehman et al. [35] demonstrated that differentiated HL-60 cells treated with siRNAs to deplete expression of PLD1 abolished basal chemokinesis, and PLD1 overexpression increased chemokinesis and chemotaxis toward CXCL8 but not CXCL5. siRNA treatment to reduce PLD2 also led to cell migration arrest. On the other hand, CXCL5 selectively increased PLD2 activity and chemotaxis of HL-60 cells overexpressing a cDNA-PLD2 construct. Hence, PLD1 is activated through CXCR1, whereas CXCR2 (and possibly CXCR1) mediates PLD2 activation. PLD catalyzes the hydrolysis of phosphatidylcholine to PA and choline [36] . PA, along with DAG (a product of PA phosphohydrolase), is able to activate NADPH oxidase in vitro [36] , thereby possibly explaining the relationship between the oxidative burst and CXCR1, and CXCR1 but not CXCR2 can activate the DAG-independent PKC isoform, although a truncated C-terminal tail mutant of CXCR2 is able to activate PKC as efficiently as CXCR1 [37] . As this mutant CXCR2 is not internalized, it is possible that signal duration may play a role in PKC activation.
RECEPTOR INTERNALIZATION AND RECYCLING
Many GPCRs undergo ligand-induced receptor internalization, although often at different rates. On human PMN, CXCR1 is internalized at higher ligand concentration than CXCR2 yet is recycled back to the membrane faster, which contrasted with the reverse pattern in transfected cells [38 -40] . Internalization at high ligand concentrations was proposed as a mechanism to allow desensitization to CXCL8 and stop the PMN once it reached the tissue site [38] . Noteworthy is the fact that CXCR2, which binds a greater number of disparate agonists than CXCR1, is known to preferentially bind and internalize in response to CXCL8 compared with other ELRϩ agonists [41] . Additionally, concomitant expression of both receptors by transfection into HEK293 cells slows desensitization of either receptor following exposure to CXCL8 when compared with transfection with a single receptor type [42] . This was not the case when CXCR1 or CXCR2 was coexpressed with CXCR4, indicating there are cross-talk interactions regulating internalization that are specific to these two receptors. Chemotaxis and granule exocytosis do not appear to be affected by receptor internalization [27] , which can be explained by the fact that greater amounts of ligand are needed for internalization versus chemotaxis and degranulation.
CXCR1 desensitization by ligand is dependent on the phosphorylation of specific serine and threonine residues on the C-terminal tail, as is the desensitizing interaction between the two receptors [42] [43] [44] . Transfection studies using RBL-3H3 cells with chimeric CXCR1/CXCR2 mutants localized the exact position of the residue leading to slower receptor internalization [45] . In mutant chimeric CXCR2 proteins, a valine present in CXCR1 at residue 199 was substituted in place of aspartate, leading to CXCL8-stimulated CXCR2 internalization similar to that of CXCR1. The authors hypothesized that the aspartate residue resulted in hydrogen-bond interactions that were necessary for rapid internalization, and valine at the same site on CXCR1 did not facilitate this type of bonding [45] .
Internalization of CXCR1 and CXCR2 is also dependent on the expression of ␤-arrestins, AP-2, GRK2, and dynamin, a GTPase [46] . The arrestin family includes ␤-arrestin 1 and 2, which bind to CXCR1 and CXCR2 and regulate cellular responses to these receptors [47, 48] . ␤-Arrestins form complexes with most GPCRs after agonist binding on the phosphorylation site of C-terminal residues by GRKs (Fig. 2) . These complexes are important for receptor desensitization as well as downstream signaling [49] . ␤-Arrestins may also mediate signaling directly through tyrosine kinases Hck and c-Fgr, leading to degranulation through CXCR1 [47] . The targeted deletion of ␤-arrestins in mice [50] and dynamin in HEK293 cells [51] led to defective clathrin-mediated internalization of CXCR2. Clathrin-coated vesicles fuse into early endosomes, where the receptors are dephosphorylated by phosphatases, including protein phosphatase 2A [52] . The phosphorylation of C-terminal residues of CXCR2 impacts on the cross-desensitization of this receptor on CXCR1, and native CXCR2 internalization is not regulated by phosphorylation but instead, by a specific amino acid motif present on the C-terminal tail, the sequence LLKIL [41, 53] . This motif binds to adaptin AP-2, which facilitates internalization. Receptors that have been dephosphorylated can be transferred to late endosomes for degradation or to recycling endosomes.
There is also evidence that the proteosomal pathway plays a role in receptor internalization. CXCR1-and CXCR2-overexpressing L1.2 cells treated with the proteosome inhibitor lactacystin, then stimulated with CXCL8, showed reduced receptor internalization [54] .
CXCR2, although internalized rapidly, is recycled and returned to the surface at a much slower rate compared with CXCR1. Recycling of the CXCR2 receptor involves proteins such as Rab11a (a member of the Rab GTPase family of proteins, ref. [55] ), as it was observed that a nonfunctional Rab11a mutant prevents the recycling of CXCR2 [56] (Fig. 2) . Furthermore, it was shown that in HEK293 cells transfected with CXCR2, the receptor associated with proteins myosin Vb and Rab family-interacting protein-2 after activation with CXCL1 [57] . Expression of mutant proteins and myosin Vb tail overexpression reduced CXCR2 recycling and subsequently reduced receptor-mediated chemotaxis, suggesting that these proteins are involved in the regulation of receptor recycling [57] . HEK cells transfected with CXCR1 or CXCR2 have elevated CXCL8-induced receptor internalization and reduced receptor recycling after being treated with cytochalasin D (depolymerizes actin filaments) [58] . This affects CXCR2 recycling more severely than CXCR1.
CROSS-AND HETEROLOGOUS DESENSITIZATION
Binding of ligand to CXCR1 or CXCR2 can affect the signaling properties of the reciprocal CXCL8 receptor; this is known as cross-desensitization. Internalization or loss of signaling of a particular receptor by ligand interactions with a second receptor type is called heterologous desensitization. CXCR1 and CXCR2 are desensitized by phosphorylation and G-protein uncoupling, resulting from the activation of other GPCRs in heterologous desensitization. CXCR1 can be desensitized by CCR5 and vice versa via PKC [37] . C5a and fMLP desensitize PMN to CXCL8-mediated responses [59] . Supporting this biochemical evidence for desensitization are in vitro PMN chemotaxis studies showing a pattern of heterologous desensitization whereby fMLP desensitized most other chemoattractants, followed by C5a [60] . It is fairly widely discussed in the literature that C5a and fMLP better desensitize the CXCR1 and CXCR2 than the reciprocal relationship, based largely on experiments with receptor-transfected cells other than neutrophils [61] . This seems to hold for some intracellular signaling events, but CXCL8 does, although not very efficiently, desensitize neutrophil responses to these alternate ligands [59] . Recently, work with a higher affinity competitive antagonist of CXCL8 [CXCL8(3-72)K11R/G31P], which interacts with the CXCR1 and CXCR2, reveals that signaling through these receptors can strongly cross-regulate heterologous GPCR in neutrophils [62] , and this suggests that the relative strength of receptor signaling could potentially differentially affect such heterologous GPCR desensitization. In addition to a hierarchy in desensitization when PMN are exposed to sequential chemoattractant gradients, there is a hierarchy when the PMN are exposed to competing gradients [63] . Despite fMLP and C5a being dominant chemoattractants, Richardson et al. [40] showed using transfection of RBL cells, that CXCR1 but not CXCR2 could in fact desensitize the formylated peptide receptor and C5aR, and that this was dependent on protracted signaling through CXCR1 by ligand compared with CXCR2.
RECEPTOR OLIGOMERIZATION
GPCRs were described initially as single polypeptides associating with the heterotrimeric G-proteins; now, there is interest in the possibility of these receptors oligomerizing, including homo-and heterodimerization. Dimerization may be liganddependent and result in alterations in receptor pharmacology and signal transduction [64] . Dimerization of some chemokine receptors may even be essential for receptor signaling [65] ; for example, mutations of CCR5 resulted in nonfunctional receptors incapable of dimerizing or signaling [66] . Trettel et al. [65] reported that CXCR2 forms a homodimer when expressed in HEK293 cells and also in cerebellar neurons. The regions associated with CXCR2 dimerization are the third transmembrane region and the first extracellular and second intracellular loops. Although the Trettel study reported that CXCR1 did not form homodimers, using a variety of technologies and coexpression of tagged CXCR1 and CXCR2 in HEK293 cells, Wilson and co-workers [67, 68] showed that CXCR1 indeed homo-oligomermizes and moreover, can form heterodimers with CXCR2. An ER-trapped form of CXCR1 prevented membrane expression of both receptors, suggesting that they associate within the ER and that CXCR1, by this mechanism, may regulate CXCR2 expression on the cell surface. Despite these findings in cell lines, oligomeriza- tion by CXCR1 or CXCR2 in PMN and the functional consequences have yet to be described.
Hetero-oligomerization is more broad than between the two CXCR molecules alone. Lax et al. [69] showed that CXCR2 coexpression with AMPA-type GluR1 in HEK2 cells increased the affinity of the GluR1 for ligand. In the reciprocal experiment, CXCL2 enhanced the spontaneous signaling of AMPA-type receptors in rat pukinje neurons in cerebellar slices. In addition to interfering with the normal pattern of signaling, receptor oligomerization can lead to unique signaling cascades. One chemokine example is CCR2 and CCR5 heterodimerization, which increased the receptor sensitivities to ligand and recruited distinct G proteins from those normally associated with either receptor alone [70] . In a second study of CXCR2 hetero-oligomerizeration, a CXCR2 antagonist enhanced ⌬ opioid peptide receptor agonist signaling, despite having no significant affinity for the receptor, showing that CXCR2 can act as an allosteric regulator for the partner receptor [71] . Lastly, a precedent has been reported in which a chemokine receptor signaled through the JAK-STAT pathway, and hetero-oligomerization was presumably critical to this phenomena. CXCR4 reportedly signals through JAK2 and JAK3 [72] , and JAK3 deficiency impairs T lymphocyte chemotactic activity to CXCL12 [73] . Whether this is a result of a direct association of the JAKs with the chemokine receptor or is an indirect association is uncertain, but the capacity to hetero-oligomerize opens this possibility for other chemokine receptors.
PMN CHEMOTAXIS
PMN chemotaxis is accomplished by the coordination of a number of events, the first of which is an increase in polymerization of actin filaments [74] . Preventing this step with cytochalasin abolishes the chemotactic response [75] . Chemotaxis in response to CXCL8 was shown using specific receptorblocking antibodies to be mediated by CXCR1, as blocking CXCR1 has been reported to almost abolish [76] or reduce [77] PMN migration. Another line of evidence that CXCL8 largely acts to promote chemotaxis through CXCR1 on PMN is from the finding that Pyk2 becomes phosphorylated following exposure to CXCL8 in a Src protein tyrosine kinase-dependent pathway, which when inhibited, reduced migration to the ligand [78] . That Pyk2 activation was linked to CXCR1 was shown using receptor-specific blocking antibodies combined with the Src inhibitor to block migration to CXCL8.
Using C-terminal tail-truncated mutants of CXCR1 revealed that this is an important domain for chemotaxis, as chemotaxis induced by CXCL8 was diminished with mutant proteins [48] . Liu-Bryan et al. [79] showed further that RBL cells transfected with CXCR1 but not CXCR2 migrated across fibronectin-coated filters in response to CXCL8, suggesting the migration was ␤ 1 integrin-dependent, and this was also a property unique to the C terminus of CXCR1. CXCR1-␤ 1 integrin-dependent migration was inhibited by pharmacological inhibitors of p38 and JNK MAPKs (with decreasing potency), implicating these kinases in the chemotactic signal.
␤ 1 integrins use FAK as an adaptor protein that internalizes signals between cytoskeletal components and extracellular signals, and FAK has now been appreciated to be part of chemokine receptor signaling also [80] . FAK relays signals among several different proteins that are involved in cell migration and adhesion, such as the Rho family GTPases, RhoA, Rac, and Cdc42. Transfection experiments using RBL cells showed a hyperphosphorylation of FAK upon CXCL8 stimulation (at desensitizing concentrations) in CXCR2 ϩ RBL but not CXCR1 ϩ RBL [81] . At lower ligand concentrations there was no difference in FAK phosphorylation between the transfected cells. Moreover, in CXCR2 ϩ RBL but not CXCR1 ϩ RBL, phosphorylation of FAK after CXCL8 stimulation was dependent on adhesion to the ECM (and thus, integrin activation), although there was a requirement for microtubules in CXCR1-expressing cells [82] . The authors hypothesized that increased FAK phosphorylation after CXCR2 activation in desensitizing conditions could prevent migration and promote firm adhesion through integrins. With regard to CXCR1, inhibition of migration under desensitizing conditions occurs independently of FAK hyperphosphorylation and integrin involvement but is dependent on other cytoskeletal structures. Chemotaxis generally involves much lower chemokine concentrations, and FAK phosphorylation between CXCR1-and CXCR2-expressing cells was not different at these low concentrations. In addition to halting migration at the site of inflammation, high chemokine concentrations may affect different neutrophil effector functions such as granule exocytosis and respiratory burst.
Evidence that the various MAPKs are activated is not always compatible with these kinases playing a role in chemotaxis. Knall et al. [83] showed that although MAPKs are activated by CXCL8, they were not critical to chemotaxis. This finding contrasts that of Lehman et al. [84] , who showed that the ERK inhibitor PD98059 dose-dependently impeded PMN ex vivo migration in a transwell assay. Cara et al. [85] showed using intravital microscopy that PMN migration to a CXCR2 ligand was dependent on p38, and rolling and adhesion to the endothelium were not. The different outcomes between studies may be a function of the particular assay used to measure chemotaxis.
Other signaling molecules important in chemotaxis to CXCL8 include cbl, a ubiquitin ligase with a tyrosine kinasebinding domain, and AKT. Both are phosphorylated upon stimulation of CXCR1 and CXCR2 overexpressing L1.2 cells, and cbl also associates with PI3K after CXCL8 stimulation [54] . Overexpressed cbl acted as a negative regulator, decreasing CXCL8-induced chemotaxis by L1.2 cells in CXCR1-and CXCR2-overexpressing cells. In addition, cells transfected with a mutant AKT had deficient CXCL8-induced migration. An overexpressed mutant of AKT also reduced cbl phosphorylation, accompanied by reduced chemotaxis, suggesting that cbl phosphorylation is inhibitory [54] .
In addition to a role for ␤ 1 integrins, we and others have studied the potential of chemoattractants to support ␤ 2 integrin (CD11b/CD18 or Mac-1)-independent PMN transintestinal epithelial cell migration. CXCL8, C5a, and leukotriene B 4 support Mac-1-independent transepithelial migration, and fMLP and CXCR2 ligands such as CXCL5 do not (ref. [86] and unpublished observations). Transepithelial migration is independent of superoxide radical production [87] , and Mac-1-independent migration does not require PLD [88] . However, the specific receptor/ligand interactions between PMN and epithelial cell and the PMN signaling mechanisms underlying Mac-1-independent migration remain elusive, although it points to activation through CXCR1 more closely resembling activation through C5a than by fMLP.
IS THERE EVIDENCE FOR A FUNCTIONAL DISTINCTION BETWEEN PMN CXCR1 AND CXCR2 IN INFLAMMATORY CONDITIONS?
Characterization of the biochemical signaling events through CXCR1 versus CXCR2 has shown there are differences at the molecular and cellular levels, albeit much of this progress is derived from cell culture and transfection experiments. We summarize these in Figure 3 , notwithstanding that it is highly likely that both receptors will be engaged in vivo. The challenge now is to align this understanding with the in vivoreported outcomes of blocking one or both receptors. The milieu of inflamed tissues is complex and typically includes multiple activators of leukocytes so it is difficult to tease-out biological consequences that can be ascribed entirely to occupancy of either receptor alone. The potential for heterologous GPCR desensitization adds another layer of complexity to this paradigm. Thus, there are a number of confounders that must be considered in trying to reach a conclusion on this question. There are multiple ligands that bind CXCR2 exclusively and none that bind CXCR1 exclusively (and only three known that bind both: CXCL8, CXCL6, and N-acetyl PGP). Therefore, it is safe to presume that PMN will typically not be activated through CXCR1 alone but may be activated through CXCR2 alone, which might indicate that blocking CXCR2 may have clear consequences in some disease states. Furthermore, most of the investigations into the biochemistry of chemoattractant receptors are based on experiments using soluble chemoattractant, and PMN more likely respond to cell (e.g., endothelial)-and matrix-fixed chemoattractant gradients (see, for example, ref. [89] ). The impact of binding a fixed ligand on internalization or desensitization of CXCR1 or CXCR2 is poorly understood. Parenchymal cells can express the receptors, so any measures taken to neutralize/ablate either receptor in vivo must prove that the resulting phenotype is directly a result of the neutralization/absence of the receptor on PMN. This confounder has indeed been exposed in bone marrow chimeric mouse experiments, in which the PMN lack the receptor but other parenchymal cells do not. Finally, as PMN respond to chemotactic signals arising from the inflamed site, the hierarchy in heterologous desensitization will dictate whether the cells migrate effectively through multiple chemoattractant gradients, as may be the case in migrating out of the blood, then through tissue, and finally across an epithelium to reach bacteria in a (e.g., airway or intestinal) lumen. With formylated peptides desensitizing all other chemoattractant receptors, it may be presumed that PMN encountering these bacterial products will be "end-stage"-activated, expressing the maximal antimicrobial phenotype. Thus, it is not necessarily in the best interest of the host to recruit PMN out of the blood using a formylated peptide receptor, as this may desensitize the cells to other chemoattractants that modulate more limited outcomes while in the tissues. CXCL8, although activating cells through CXCR1 and CXCR2, desensitizes the PMN to CXCR2 ligands. The broader biochemical outcomes behind CXCR1 activation compared with CXCR2 may signify that this receptor has a more regulatory and therefore, desirable function in the context of PMN activation. CXCR1 is internalized at a slower rate, recycled more completely, and requires a more prolonged signal compared with CXCR2 to activate downstream effector molecules. The prolonged signal stimulates respiratory burst, important in killing microbes, but also with the potential of extensive tissue damage (Fig. 3) . Thus, we may expect that PMN recruitment using CXCR2 ligands may precede using CXCL8 to activate antimicrobial defenses, possibly followed by final and maximal activation by bacterial products acting through formyl peptide receptor-1. CXCR2, in this context, would serve as a pure chemoattractant, and CXCR1 act more to activate microbicidal properties and possibly slow migration by down-regulating CXCR2. This hypothesis is supported by recent evidence that PMN lose their microbicidal capacity when stimulated with CXCL8 in the presence of CXCR1-but not CXCR2-blocking antibodies [90] . The presence of only CXCR2 ligands may limit tissue damage during inflammation; however, there are few studies in which only CXCR2 ligands are elicited.
PMN have been implicated as contributing to the pathology of a variety of human inflammatory diseases characterized by high levels of CXCL8 and this has motivated a search for mutations in the receptors that might make PMN hyper-or hyporeactive and predispose the patient to a particular condition. It is also popular to model these diseases in rodents, where gene knockouts are available, or experimental therapeutics can be applied. This review will expand on some of examples presented in three general groupings: human diseases for which mutations regulating expression of CXCR1 or CXCR2 on PMN are thought to be associated with a predisposition to disease; CXCR2 gene knockout mouse studies in disease models, in which PMN are thought to play a role (see Table 2 ); and studies in which chemical inhibitors or antibodies are used to block receptor function with an impact on disease (see Table 3 ). The abundant studies in which receptor levels on PMN are found altered likely as a consequence of the disease, although it may affect the outcome of the disease, will not be considered.
One condition where associations between altered CXCR expression and possible PMN activity have been sought is recurrent UTI ( Table 1) . UTI are commonly caused by uropathogenic Escherichia coli and are associated with robust PMN infiltration of the mucosa and migration across the ureter epithelium, where they can be detected in the urine (pyurea). CXCL8, up-regulated during UTI, can also be detected in the urine [97] [98] [99] . These clinical findings (and results from mouse experiments below, which strongly implicate a critical role for PMN in resistance to infection) led to interest in whether PMN bactericidal capacity or possibly migration is compromised in patients. The first study to examine whether there is a relationship between CXCR1 and CXCR2 on patient PMN and susceptibility to UTI reported that infection-free children, who had experienced recurrent UTI previously, showed significantly lower surface CXCR1 but no differences in levels of surface CXCR2; however, no receptor gene polymorphisms were reported [100] . This finding of low CXCR1 on PMN was repeated in a subsequent study of children with acute pyelonephritis, and additionally, polymorphisms in the IL-8RA gene were identified which were linked mechanistically to reduced levels of mRNA for the receptor [92] . A study of children who experienced their first UTI also had a significant association with polymorphisms in the CXCL8 gene, which results in high relative production of the chemokine. A subset of these patients was also positive for a dimercapto-succinic acid scan, an indication of a more severe upper-tract injury [93] . Finally, in contrast to the finding of low CXCR1 in pediatric patients, a study examining premenopausal women with recurring UTI found similar expression levels of CXCR1 on patient PMN compared with women who had no UTI history, but the patients had significantly lower levels of CXCR2 [91] . The diversity of these findings speaks to the need to use functional measures of patient PMN to strengthen any association between receptor expression levels and the possibility that this contributes to the patients' risk of disease. Notwithstanding the difficulty of obtaining multiple samples, none of the studies reports a correlation between pyurea and polymorphisms or the capacity of patient PMN to migrate in vitro or generate superoxide radicals. Such analyses may begin to better link the patients' risk more directly to functional consequences behind altered receptor expression levels on PMN. Still, the studies do suggest that the CXCL8/PMN axis is particularly important in controlling these infections and possibly by recruiting and activating the cells.
PMN have long been thought to play an integral role in pulmonary defenses but play a pathogenic role in inflammatory diseases such as COPD and asthma, and CXCL8 levels in sputum are negatively correlated with measures of lung function. This has led to studies about whether susceptibility can be attributed to genetic factors. One such study found significant associations between two tightly linked missense mutations in IL-8RA with COPD and children with asthma versus healthy controls [94] . A second study failed to find the same pattern in IL-8RA but did find polymorphisms in the CXCL8 gene that linked asthma and severe infant cases of respiratory syncytial virus [95] . Unfortunately, none of these polymorphisms are characterized in terms of increasing or compromising PMN activity.
The inflammatory bowel diseases, Crohn's disease and UC are thought to be exacerbated by PMN. Both diseases, but par-
TABLE 1. Human CXCR1,2 Polymorphisms Associated with Diseases with Presumed PMN Involvement

Disease
Polymorphism Finding/conclusion Reference UTI S276T, R335C, S276R Polymorphisms were detected at exon 2 of CXCR1, but their frequencies did not differ between patients and controls. Low level of CXCR2 expression on PMN may increase the risks of premenopausal women to UTI.
[91]
Acute pyelonephritis ϩ217C/G and ϩ3081C/T Identified two known polymorphisms and three unique mutations in the CXCR1 gene associated with patients, suggesting a novel genetically determined cause of susceptibility.
[92]
Acute pyelonephritis IL-8, -251A, and ϩ2767A
The gene for the proinflammatory chemokine IL-8 is involved in susceptibility to acute pyelonephritis during upper UTI in children with or without vesicoureteral reflux.
[93]
COPD and asthma IL-8RA M31R and R335C The frequencies of the IL-8RA M31R and R335C alleles were increased significantly in patients with COPD and in children with asthma.
[94]
Asthma and respiratory syncytial virus (RSV)
IL8-781C/T
Report an association between the IL-8 polymorphism-781C/ T as well as IL-8 haplotypes with asthma. IL-8RA not thought to play a major role in the genetics of either disease.
[95]
Idiopathic bronchiectasis and ulcerative colitis CXCR1 (ϩ12607 G/C) CXCR2 polymorphism was distributed similarly in the idiopathic bronchiectasis group and controls, suggesting that this polymorphism is not associated with disease susceptibility.
[ 96] ticularly UC, have PMN infiltration of the mucosa and lumen (crypt abscesses) as hallmarks of inflammation. In fact, the concentration of PMN products found in patient stool correlates directly with disease severity [101] . There is copious evidence showing that CXCL8, among other chemokines, and the number of cells bearing CXCR1 and CXCR2 are highly elevated in the inflamed mucosa [102] [103] [104] [105] , yet there is a paucity of analyses, such as those done with the recurrent UTI patients. In fact, one study found no association between a polymorphism in CXCR1 (12607 G/C) that results in CXCL8 binding with higher affinity and UC patients, with or without idiopathic bronchiectasis, an autoimmune lung condition associated with some UC patients [96] . More evidence for a therapeutic effect of antagonizing the CXCL8/CXCR axis in colitis has been derived from rodent studies. Table 2 lists studies in which CXCR2 gene knockout mice were used in models of disease, and Table 3 lists studies in which CXCR2-blocking agents were used, all studies in which PMN are thought to contribute to the pathology. Overall, the studies demonstrate that impeding PMN in infectious models typically worsen the outcome, whereas impeding PMN in sterile injuries specifically result in less pathology, although the confidence with which PMN are implicated varies as a result of confounding parameters in the models. Still, there are contrary reports that show PMN depletion actually attenuates pathology in the face of microbial challenge. For example, depleting calves of PMN prior to pulmonary infection with Mannheimia haemolytica reduces mortality and morbidity [135] .
RODENT STUDIES IMPLICATING CXCR2 ON PMN IN DISEASE
We have also reported recently that reducing neutrophilic pathology with a combined CXCR1/CXCR2-competitive antagonist in a guinea pig model of aspiration pneumonia did not predispose to bacterial outgrowth in the airway (Xixing Zhao, Jennifer Town, J. R. Gordon, unpublished results). Studies in mice deficient in CXCR2 or treated with blocking antibodies strongly implicated this receptor in host susceptibility to an experimental UTI. PMN in CXCR2-deficient mice accumulated in the ureter mucosa and failed to migrate across into the ureter lumen, such that the mice failed to resolve the infection [112] and developed pyelonephritis [113] . A similar phenotype was observed with administration of a blocking antibody to CXCR2 to mice with experimental UTI [136] . It is noteworthy that PMN extravasated into the tissue, indicating that other chemoattractants are important in PMN migration into the ureter mucosa. Under inflammatory conditions, the (human) ureter epithelium also expresses CXCR1 and CXCR2, which confounds the interpretation that loss of the
TABLE 2. CXCR2 Gene Knockout Mouse Studies Implicating PMN in Disease Models
Disease Finding/conclusion Reference Hyperoxia-induced lung injury Inhibition of CXC chemokine ligands/CXCR2 interaction in CXCR2 -/-mice exposed to hyperoxia reduced PMN sequestration and lung injury significantly. [ 
106]
Pseudomonas aeruginosainduced pneumonia CXCR2 -/-and antibody-injected mice blocked PMN recruitment and increased mortality as a result of decreased bacterial clearance. Transgenic mice overexpressing KC resulted in enhanced clearance of bacteria after P. aeruginosa challenge. [107] Cecal ligation and puncture Absence of CXCR2 protects mice from septic injury, potentially by delaying inflammatory cell recruitment.
[108]
DSS-induced chronic colitis CXCR2 -/-mice failed to show PMN infiltration into the mucosa and consistent with PMN-mediating tissue damage, mice showed reduced clinical symptoms and mucosal damage. [109] DSS-induced acute colitis CXCR2 -/-mice and anti-CXCR2-injected mice show reduced PMN infiltration into the mucosa, no ulcers, and less clinical disease. Eosinophil infiltration was CXCR2-independent.
[110]
LPS-induced lung injury
Chimeric study, wild-type reconstituted with CXCR2 -/-cells showed partial PMN infiltration and CXCR2 -/-mice reconstituted with wild-type cells showed a large defect, suggesting nonhematopoetic cell CXCR2 is important in PMN migration, independent of receptor expression by PMN.
[111] UTI CXCR2 -/-PMN were unable to cross the epithelial barrier and accumulated in high numbers in the tissues, eventually resulting in pyelonephritis. The failure to migrate into the ureter lumen was a result of loss of the receptor on PMN, shown using bone marrow radiation chimeric mice. [112, 113] Influenza virus infection CXCR2 mediates PMN recruitment to the lung during influenza virus infection, but CXCR2 is not required for virus clearance.
[114]
Ozone-induced airway inflammation CXCR2 is essential for maximal chemokine-directed migration of PMN to the airway spaces. CXCR2 -/-mice had significantly fewer PMN in BALF.
[115]
P. aeruginosa and helminth antigen-induced Keratitis CXCR2 -/-animals had minimal PMN recruitment into the site of the cornea infection. CXCR2 is critical to recruit PMN into the cornea and may indicate a target for immune intervention in PMN-mediated corneal inflammation. [116, 117] receptor on PMN alone is necessary to achieve the susceptible phenotype. Migration of human PMN across an E. coli-infected human urinary epithelial monolayer was blocked by antibodies to CXCR1 applied to the PMN, but migration was also reduced when the antibodies were applied to the epithelium. The same result was not observed using blocking antibodies to CXCR2 [112, 137] . Nevertheless, it was shown recently, using bone marrow radiation chimeric mice, that the absence of the receptor on PMN is the major factor behind the impeded migration into the lumen [113] . These studies establish the association between PMN infiltration into the lumen and susceptibility to UTI, yet the confounding pyelonephritis suggests that other activating factors are present in the model. Similar to the UTI studies, multiple rodent models of colitis report elevated levels of mucosal chemoattractants, including the ELR ϩ CXC chemokines and implicate PMN in the pathology. It is unlikely that a single CXC chemokine is elicited during colitis, as Kwon et al. [138] reduced endogenous mucosal expression of LPS-induced CXC-chemokine (LIX, the homologue of CXCL5) using antisense oligodeoxynucleotides during DSS colitis yet reduced PMN infiltration by roughly half, the remaining infiltration likely being a result of other chemoattractants. In addition to characterizing endogenous chemoattractants during colitis, mice have been engineered to overexpress CXC chemokines and had human CXCR2 "knocked in," substituting for the endogenous gene [139] . Transgenic intestinal epithelial cell overexpression of MIP-2 resulted in exacerbated pathology, including increased numbers of infiltrating PMN when mice were challenged with DSS, indicating that chemoattractants arising from the epithelium indeed recruit PMN [140] . Epithelial cell recruitment was also shown elegantly using mice engineered to inducibly express human CXCL8 in the distal ileum, cecum, and proximal colon epithelium under the control of the fatty acid-binding protein promoter coupled with a doxycycline promoter [141] . Mice fed doxycycline experienced a large PMN infiltration into the intestinal mucosa, and the cells accumulated between the epithelial cells yet did not show signs of degranulation [141] . Moreover, PMN did not cross into the lumen, leading the authors to speculate that a second chemoattractant would be necessary to recruit the PMN beyond the epithelium. Thus, despite the molecular evidence showing that CXCL8 will activate PMN, and therefore the cells ought to cause tissue damage, PMN recruited using CXCR2 to the mucosa were not activated, and there was no pathology associated with PMN recruitment. This suggests that the broad, activating properties of CXCL8 in vitro may not apply in vivo, possibly as a result of the concentrations of the chemokine in vivo, the lack of a CXCR1 homologue on mouse PMN, or possibly inhibitors of cell activation present in the mucosa. Alternately, it may be that CXCL8 is not an activator of PMN per se but rather, that its primary task is to recruit these cells to sites where other signals (e.g., TLR, fMLP) activate them. For example, although CXCL8 induces intracellular calcium flux effectively and activates CD11b, it does not mobilize secondary or tertiary granules efficiently (J. Town, J. R. Gordon, unpublished results). Intravascular CXCR signaling (via endothelial glycosaminoglycan-bound chemokine) is critical to integrin activation, which is a prelude to cellular arrest and diapedesis, but overt PMN activation prior to arrest would be highly pathogenic. As blood concentrations of CXCL8 were over 10 times higher in the transgenic mice after doxycycline feeding compared with wild-type, it is possible that PMN became desensitized during the migration process and were no longer responsive to the chemokine once in the mucosa. It is also possible that the induced CXCL8 acts indirectly to recruit PMN into the intestine by first acting on other cell types bearing CXCR2. This could be assessed using radiation chimeras of the transgenic strain receiving CXCR2-deficient bone marrow cells.
Notwithstanding this apparent paradox of a lack of pathology despite high numbers of infiltrating PMN, multiple reports of induced colitis in CXCR2-deficient mice or in which PMN infiltration is blocked by antibodies or chemical inhibitors, typically also convey reduced colon pathology [109, 110, 130] . Use of CXCR2 by rat PMN early during acute inflammation versus later was shown in a model of TNBS-induced colitis. Rats were protected acutely (8 h) when treated with an antiserum to CXCR2; however, chronic administration of the antibody did not reduce late PMN migration into the mucosa, suggesting that CXCR2 blockade is beneficial in the initial stages of an inflammatory insult [131] . Still, these studies cannot rule out an impact of non-PMN CXCR2-expressing cells.
Convincing evidence that nonleukocyte expression of CXCR2 can impact on PMN infiltration was shown in a model of murine lung pathology. CXCR2 knockout mice reconstituted with wild-type bone marrow had reduced numbers of infiltrating PMN following LPS inhalation, and significant numbers of PMN continued to infiltrate the challenged lungs of wild-type mice reconstituted with bone marrow from knockout mice [111] . The latter observation was partially a result of non-CXC chemoattractants being produced in the LPS-challenged lung, but the authors ultimately determined that endothelial cell expression of CXCR2 was critical to facilitating PMN infiltration. Increased lung vascular permeability in the model required expression of CXCR2 on nonhematopoietic cells. Epithelial expression of CXCR1 or CXCR2 may also contribute to such pathology. It has been shown that antagonizing ELR-CXC chemokines reduces human bronchial epithelial cell CXCL1 and CXCL8 expression significantly in response to bacterial endotoxin signaling, presumably by blocking an autocrine inflammatory cycle [62] . Collectively, these model studies serve to show that there are typically additional chemoattractants to the ELR ϩ CXC chemokines and second, how nonhematopoietic expression of CXCR2 can confound the interpretation of PMN infiltration as a result of ELR ϩ CXC chemokines. Further, regarding nonleukocyte expression of CXCR2 and with precedents from the urinary tract and bronchial epithelium, investigators have sought whether the intestinal epithelium expresses CXCR1 and/or CXCR2 [142, 143] . The evidence is that human colon carcinoma cells express CXCR1 but not CXCR2 [4] and that CXCR1 is up-regulated in situ on epithelial cells near ulcerated areas in UC [143] . This further highlights a potential role for CXCR1 in promoting PMN re- 
NOVEL CXCR1 AND CXCR2 ANTAGONISTS
The evidence from antibody inhibition studies and gene knockout strains used in models of inflammation makes a compelling argument that preventing PMN infiltration is associated with reduced tissue damage. This association has motivated a search for nonantibody compounds that antagonize CXCR1 and CXCR2 (human and other species) or CXCR2 in the case of the mouse, and many of the chemicals under investigation show cross-species reactivity. Recently, others [144, 145] reviewed the chemistry of many of these compounds. One early example was antileukinate, a hexapeptide with the sequence Ac-RRWWCR-NH 2 , first described to block CXCL8 binding to human PMN and CXCL8-induced PMN degranulation and chemotaxis [146] . It was subsequently reported that s.c. injections were effective in reducing, although not ablating, murine lung injury severity and induced acute pancreatitis [147] . Administering antileukinate after commencing pancreatic damage proved as effective as pretreatment in the pancreas and the lung [147] . Antileukinate has been shown to be effective in reducing the severity of other lung injury models [148 -150] . Other CXCR2 inhibitors have been used to attenuate induced lung inflammation associated with significantly reduced (ϳ50%) PMN infiltration, such as Reparixin [118] and SCH-N [129] . Sch527123 was shown to cross-react among mice, rats, and cynologus monkey but bound with higher affinity to monkey CXCR2 than CXCR1. Yet, used orally, Sch527123 reduced PMN infiltration dose-dependently, following repeat bronchoscopy of the primates [121] . In a model of newborn rat hyperoxia, antagonism of CXCR2 using SB265610 resulted in a reduced level of hydroxyl radical and lipid peroxidation [151] . Thus, the prevailing evidence is in favor of antagonizing CXCR2 to treat inflammatory respiratory disease, although these studies do not necessarily implicate CXCR2 directly on PMN as causal in the models. Another approach to antagonizing CXCR1 and CXCR2 is to develop chemokine analogs that have been mutated to bind but not transduce signals, such as truncated N-terminal ELR mutations of CXCL8 [26, 152] . A recent CXCL8 analog, G31P (CXCL8(3-72)K11R/G31P), a human N-terminal/bovine C-terminal chimeric CXCL8, is based on an antagonist form of mutated bovine CXCL8 [123, 124] . These analogs antagonized CXCR1 and CXCR2 significantly by inhibiting CXCL8-mediated chemotaxis and superoxide production by human peripheral blood PMN in vitro and inflammatory damage in LPSchallenged guinea pig lungs, even when given well after the responses had begun to develop. Thus, a number of strategies to develop ligand analogs have been successful in vitro and in rodent applications. Bovine G31P antagonizes endotoxin-induced neutrophilic inflammation by Ͼ95% in the skin of cattle [124] and pigs [153] . It also reduces clinical signs and airway neutrophilia (by 85%) in piglets with severe airway endotoxemia. A fully human form of CXCL(3-72)K11R/G31P reduced airway neutrophilia in guinea pigs with an acidified gastric contents-induced aspiration pneumonia by ϳ85%, without predisposing airway bacterial outgrowths (X. Zhao, J. Town, J. R. Gordon, unpublished data). This drug also reduced mesenteric artery ischemia-reperfusion injury-induced mortality by 50% in a rat model, and 60 -95% reduced local and remote (i.e., lung) organ injury in these animals [154] .
Despite the encouraging outcomes in animal models of human disease, few of these molecules have been used in humans. In fact, anti-CXCL8 therapies have been used in COPD with disappointingly little improvement in the patients, possibly as other ELRϩ CXC chemokines, in addition to CXCL8, are active, which would suggest that simultaneous targeting of all of the ELRϩ CXC chemokines could provide greater protective advantages. This fact and the emerging understanding that CXCR2 mediates other cell-type activities, including in [134]
COPD, have led to early human trials of CXCR2 antagonists as a therapy for COPD [145, 155] . The diversity of targets for ELR ϩ CXC chemokines only seems be growing and recent attention has turned to a role for CXCL8 in angiogenesis and cancer growth. For example, human intestinal microvascular endothelial cells express CXCR2 but not CXCR1, and CXCL8 induces stress fiber formation and migration in the endothelial cells [156] . Blocking antibodies to CXCR2 abolished this response, highlighting the importance of CXCL8/CXCR2 signaling in angiogenesis. Antileukinate was shown to prevent the growth of human endothelial cells, indicating its possible use in preventing angiogenesis [157] . Antileukinate is also effective in inhibiting growth of human cancer cells in vitro [158] and in vivo in nude mice [159, 160] . These new cellular targets may well expand the use of antireceptor therapies but also confound the interpretation that the therapeutic effects of CXCR1/CXCR2 blockade are strictly dependent on its impact on PMN.
CONCLUSIONS
An abundant literature based on exposure of PMN to soluble chemokines has identified some differences in the molecular and biological outcomes of stimulation through CXCR1 versus CXCR2 (Fig. 3) . The prevailing evidence suggests that activation through CXCR1 results in a wider array of antimicrobial processes than are stimulated through CXCR2. Although both receptors are capable of mediating chemotaxis, it may be that CXCR2 responds to lower concentrations of ligand (and ligands that do not bind CXCR1) in the capacity of a pure chemoattractant. This may be better addressed with the development of CXCR2-specific inhibitors or those that target the CXCR1 and CXCR2 effectively. This understanding has not translated into clear effector roles for PMN depending on their use of one or both receptors. There are several human diseases for which mutations in one or the other receptor gene have been associated but no consistent pattern has emerged, for example, loss of function mutations in CXCR1 resulting in increased susceptibility to infection. PMN function has not been typically characterized in the population of patients with these mutations. Despite clear evidence of a clinical benefit in a number of induced disease models, there are limitations in the usefulness of CXCR2 gene-knockout mice in explaining the contribution of PMN to disease. This is because CXCR2 is expressed on other cell types, including on cells that impact indirectly on PMN migration, thus confounding the interpretation even when PMN tissue infiltration is reduced. Still, the phenotypes of CXCR2-knockout mice in these disease models are striking, considering the redundancy among PMN chemoattractants generated in a typical site of inflammation. The outcomes using gene-knockout mice have generally been supported by in vivo blockade of CXCR2 in rodents, and these studies provide encouraging results that antagonism of CXCR1 and CXCR2 can provide clinical benefit. Finally, another confounder in addition to non-PMN expression of the receptor becomes apparent when attributing any clinical benefit to alterations in PMN activity. It is likely that interfering with CXCR2 impacts on other receptor systems, PMN and otherwise.
